Gift Aid Declaration
Completing this form will enable Retina UK to claim tax back on eligible donations. It means that for every £1 you donate to Retina UK we can claim back 25p at no extra cost to you.
Search
Search results
jCyte have released additional preclinical data regarding jCell
jCyte have released additional preclinical data regarding jCell
Significantly worse vision found in female carriers of X-linked RP and Choroideremia
It was previously believed that female carriers of X-linked inherited retinal diseases (IRDs) like X-linked retinitis pigmentosa (RP and Choroideremia) remained unaffected by sight loss.
Podcast: Introducing our new chair
A new Retina UK podcast that introduces our new chair of trustees, Kathy Evans.
Webinar: Supporting Retina UK and what it can do for you
Our speakers tell us about the many positive impacts fundraising has had for them, including for their emotional wellbeing, and the many surprises along the way.
Meet our community: James Clarke
Aged 20, James was diagnosed with retinitis pigmentosa at a routine eye appointment in September 2015 and registered partially sighted, just prior to buying his first car and taking his driving test.
Peak District Challenge
Walk, jog or run 25, 50 or 100km from the Bakewell Base Camp and take in Derbyshire’s finest scenery.
Gene therapy treatment Luxturna accepted for use in Scotland
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
Leaflet: Are you supporting someone with inherited sight loss
A guide for professionals. Retina UK is a national charity. We offer information and support to people affected by inherited sight loss to enable them to lead better lives today and fund medical research to accelerate the search for treatments for the future. We also support professionals working with them.
ProQR announces suspension of LCA10 and USH2A clinical trials
Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.